IN2015DN01115A - - Google Patents

Info

Publication number
IN2015DN01115A
IN2015DN01115A IN1115DEN2015A IN2015DN01115A IN 2015DN01115 A IN2015DN01115 A IN 2015DN01115A IN 1115DEN2015 A IN1115DEN2015 A IN 1115DEN2015A IN 2015DN01115 A IN2015DN01115 A IN 2015DN01115A
Authority
IN
India
Prior art keywords
polypeptide
constructs
heteromultimer
monomeric
transporter
Prior art date
Application number
Other languages
English (en)
Inventor
Surjit Bhimarao Dixit
Igor Edmondo Paolo DANGELO
Mario Sanches
Gordon Yiu Kon Ng
Original Assignee
Zymeworks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks Inc filed Critical Zymeworks Inc
Publication of IN2015DN01115A publication Critical patent/IN2015DN01115A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN1115DEN2015 2012-07-13 2013-07-12 IN2015DN01115A (pm)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261671640P 2012-07-13 2012-07-13
US201261697245P 2012-09-05 2012-09-05
US201361758701P 2013-01-30 2013-01-30
US201361845945P 2013-07-12 2013-07-12
PCT/US2013/050408 WO2014012082A2 (en) 2012-07-13 2013-07-12 Multivalent heteromultimer scaffold design an constructs

Publications (1)

Publication Number Publication Date
IN2015DN01115A true IN2015DN01115A (pm) 2015-06-26

Family

ID=49916710

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1115DEN2015 IN2015DN01115A (pm) 2012-07-13 2013-07-12

Country Status (7)

Country Link
US (3) US9388231B2 (pm)
JP (1) JP6498601B2 (pm)
CN (1) CN104768571B (pm)
AU (1) AU2013289881B2 (pm)
CA (1) CA2878640C (pm)
IN (1) IN2015DN01115A (pm)
WO (1) WO2014012082A2 (pm)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101973930B1 (ko) 2010-11-05 2019-04-29 자임워크스 인코포레이티드 Fc 도메인 내의 돌연변이를 갖는 안정한 이종이량체 항체 디자인
US9499605B2 (en) 2011-03-03 2016-11-22 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
KR102052774B1 (ko) 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
IN2015DN01115A (pm) 2012-07-13 2015-06-26 Zymeworks Inc
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014209855A1 (en) * 2013-06-24 2014-12-31 Anthrogenesis Corporation Methods of expanding t cells
RU2723940C2 (ru) * 2014-03-21 2020-06-18 Экс-Боди, Инк. Биспецифические антигенсвязывающие полипептиды
AU2015265457B2 (en) 2014-05-28 2021-02-18 Zymeworks Bc Inc. Modified antigen binding polypeptide constructs and uses thereof
CA3138083A1 (en) * 2014-12-22 2016-06-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
JP2018524373A (ja) 2015-07-15 2018-08-30 ザイムワークス，インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
JP7028802B2 (ja) 2016-10-11 2022-03-02 ウェルスタット オフサルミックス コーポレーション 短鎖型桿体由来錐体生存因子及び親水性ペプチド間の融合タンパク質
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
JOP20190222A1 (ar) 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
WO2018195416A1 (en) * 2017-04-21 2018-10-25 Mayo Foundation For Medical Education And Research Polypeptide-antibody complexes and uses thereof
BR112019024127A2 (pt) 2017-05-24 2020-06-23 Pandion Therapeutics, Inc. Imunotolerância alvejada
KR102611853B1 (ko) 2017-06-30 2023-12-08 자임워크스 비씨 인코포레이티드 안정화된 키메라 fabs
AR112603A1 (es) 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019157039A1 (en) * 2018-02-06 2019-08-15 Mayo Foundation For Medical Education And Research Antibody-peptide complexes and uses thereof
AU2019235634A1 (en) 2018-03-13 2020-10-22 Zymeworks Bc Inc. Anti-HER2 biparatopic antibody-drug conjugates and methods of use
JP7383704B2 (ja) * 2018-06-07 2023-11-20 カリナン オンコロジー インコーポレイテッド 多重特異性結合タンパク質およびその使用方法
CN120518763A (zh) * 2019-04-01 2025-08-22 诺和诺德股份有限公司 针对利拉鲁肽的抗体及其用途
KR102244760B1 (ko) * 2019-04-29 2021-04-27 주식회사 다나그린 혈청유래 단백질을 포함하는 다공성 세포지지체 및 제조방법
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CN114126635A (zh) * 2019-05-29 2022-03-01 Cue生物制药股份有限公司 多聚体t细胞调节多肽及其使用方法
US12428480B2 (en) 2019-12-11 2025-09-30 Cullinan Therapeutics, Inc. Anti-CD19 antibodies and multi-specific binding proteins
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
KR102501387B1 (ko) 2020-09-25 2023-02-24 주식회사 프로앱텍 요산산화효소-알부민 접합체, 그 제조방법 및 용도
EP4218825A4 (en) * 2020-09-25 2025-03-19 Proabtech Inc. Conjugate of functional polypeptide variant, and use thereof
CN114736291B (zh) * 2021-01-07 2023-08-11 中国科学院微生物研究所 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
CN113563474B (zh) * 2021-06-11 2023-05-02 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） EpCAM-CD16-NKG2D三特异性抗体及其应用
EP4469490A2 (en) * 2022-01-28 2024-12-04 Sigilon Therapeutics, Inc. Compositions, devices and methods for treating cns disorders
CN115057925B (zh) * 2022-06-22 2024-03-26 中国检验检疫科学研究院 一种抗赤羽病病毒单克隆抗体及其应用
CN117024578B (zh) * 2023-07-19 2024-05-24 重庆明道捷测生物科技有限公司 一种用于捕获HBV核心颗粒的IgG抗体及应用
CN116990504B (zh) * 2023-09-27 2023-12-01 苏州旭光科星抗体生物科技有限公司 检测人可溶性cd4的双抗体夹心酶联免疫试剂盒

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CA1319120C (en) 1985-04-01 1993-06-15 John Henry Kenten Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8510219D0 (en) 1985-04-22 1985-05-30 Bass Plc Isolation of fermentation products
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
JPS6296086A (ja) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol 複合プラスミド
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8615701D0 (en) 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
US4857467A (en) 1986-07-23 1989-08-15 Phillips Petroleum Company Carbon and energy source markers for transformation of strains of the genes Pichia
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
DK159088C (da) 1988-04-06 1991-01-28 Oce Helioprint As Skanner til aftastning af en original
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
KR100195632B1 (ko) 1988-07-23 1999-06-15 스티븐 조지 가랜드 펩티드 및 dna 배열
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DD275463A1 (de) 1988-09-07 1990-01-24 Forschungsstelle Fuer Medizini Verfahren zur herstellung von serumeiweissen mit gesteigertem dipolmoment zu therapeutischen zwecken
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5108910A (en) 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5780594A (en) 1993-03-01 1998-07-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Biologically active protein fragments containing specific binding regions of serum albumin or related proteins
US6001606A (en) 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU3134695A (en) 1995-05-05 1996-11-21 Human Genome Sciences, Inc. Human chemokine beta-8, chemokine beta-1 and macrophage infl ammatory protein-4
US6291207B1 (en) 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
EP1088888A4 (en) 1998-05-14 2005-03-16 Merck Patent Gmbh MERGED PROTEIN
WO2001007608A1 (en) 1999-07-21 2001-02-01 Human Genome Sciences, Inc. Keratinocyte derived interferon
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HK1042052A1 (zh) 1999-02-08 2002-08-02 Human Genome Sciences, Inc. 内皮血管生长因子-2
EP1206541A4 (en) 1999-08-05 2002-09-18 Human Genome Sciences Inc SECRETIED LYMPHOCYTE ACTIVATION MOLECUE, ENRICHED BY DENDRITIC CELLS
JP2003511012A (ja) 1999-09-24 2003-03-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ３２個のヒト分泌タンパク質
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US20050100991A1 (en) 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
CN101712722A (zh) 2000-12-07 2010-05-26 伊莱利利公司 Glp-1融合蛋白
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP2292271A3 (en) 2001-10-10 2011-09-14 BioGeneriX AG Remodelling and glycoconjugation of an antibody
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
CN101987871A (zh) 2002-09-27 2011-03-23 赞科股份有限公司 优化的Fc变体及其产生方法
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
WO2004082640A2 (en) 2003-03-19 2004-09-30 New Century Pharmaceuticals, Inc. Human serum albumin conjugates with therapeutic compounds
PL1729795T3 (pl) 2004-02-09 2016-08-31 Human Genome Sciences Inc Białka fuzyjne albuminy
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
WO2007097812A2 (en) 2005-11-03 2007-08-30 Genentech, Inc. Therapeutic anti-her2 antibody fusion polypeptides
US8441210B2 (en) 2006-01-20 2013-05-14 Point Somee Limited Liability Company Adaptive current regulation for solid state lighting
WO2007136778A2 (en) 2006-05-19 2007-11-29 Teva Pharmaceutical Industries, Ltd. Fusion proteins, uses thereof and processes for producing same
EP2027153B1 (en) 2006-05-25 2014-04-30 Bayer Intellectual Property GmbH Dimeric molecular complexes
ES2910207T3 (es) 2006-06-14 2022-05-11 Csl Behring Gmbh Proteínas de fusión escindibles proteolíticamente que comprenden un factor de coagulación de la sangre
WO2008140493A2 (en) 2006-11-21 2008-11-20 The Regents Of The University Of Californina Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
WO2008131242A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2009012784A2 (en) 2007-07-20 2009-01-29 Nya Hamlet Pharma Ab Methods for preparing cytotoxic complexes of emulsifier and fatty acid
US8197196B2 (en) 2007-08-31 2012-06-12 General Electric Company Bushing and clock spring assembly for moveable turbine vane
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
EP2247618B1 (en) 2008-01-25 2014-06-11 Amgen, Inc Ferroportin antibodies and methods of use
DE112009000507T5 (de) * 2008-03-05 2011-02-10 Ablynx Nv Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
CA3020928C (en) 2008-05-15 2023-08-08 National Research Council Of Canada Expression systems encoding truncated ebna1, methods, and use thereof
US20120100558A1 (en) 2008-09-08 2012-04-26 Hanash Samir M Lung cancer diagnosis
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
KR101722961B1 (ko) * 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
AU2010234459A1 (en) * 2009-04-08 2011-11-03 The Regents Of The University Of California Human protein scaffold with controlled serum pharmacokinetics
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011047180A1 (en) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
CN105567699A (zh) 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 白蛋白变体
JP5960598B2 (ja) * 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
WO2011069090A1 (en) 2009-12-04 2011-06-09 Alavita Pharmaceuticals, Inc. Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine
CA2794708C (en) 2010-03-29 2021-11-16 Zymeworks Inc. Antibodies with enhanced or suppressed effector function
MX346731B (es) * 2010-04-23 2017-03-30 Genentech Inc * Producción de proteínas heteromultiméricas.
CA2797981C (en) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
US9714294B2 (en) 2010-05-27 2017-07-25 Genmab A/S Monoclonal antibodies against HER2 epitope
LT2591006T (lt) 2010-07-09 2019-08-26 Bioverativ Therapeutics Inc. Apdorojamos viengrandės molekulės ir iš jų gauti polipeptidai
KR101973930B1 (ko) 2010-11-05 2019-04-29 자임워크스 인코포레이티드 Fc 도메인 내의 돌연변이를 갖는 안정한 이종이량체 항체 디자인
US9499605B2 (en) * 2011-03-03 2016-11-22 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
SI2748201T1 (en) 2011-08-23 2018-03-30 Roche Glycart Ag Bispecific antigen-binding molecules that activate T-cells
KR102052774B1 (ko) 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
US20130336973A1 (en) 2012-05-10 2013-12-19 Zymeworks Inc. Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain
RU2014148704A (ru) 2012-05-10 2016-07-10 Займворкс Инк. Конструкции одноруких моновалентных антител и их использование
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
AU2013289883B2 (en) * 2012-07-13 2018-11-01 Zymeworks Bc Inc. Bispecific asymmetric heterodimers comprising anti-CD3 constructs
IN2015DN01115A (pm) * 2012-07-13 2015-06-26 Zymeworks Inc
CN104640561A (zh) 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
JP2016520586A (ja) 2013-05-08 2016-07-14 ザイムワークス，インコーポレイテッド 二重特異性ｈｅｒ２およびｈｅｒ３抗原結合性構築物
JP2016531100A (ja) 2013-07-12 2016-10-06 ザイムワークス，インコーポレイテッド 二重特異的なｃｄ３及びｃｄ１９抗原結合構築物
WO2017100363A1 (en) 2015-12-08 2017-06-15 Smartcar, Inc. System and method for processing requests

Also Published As

Publication number Publication date
JP2015524799A (ja) 2015-08-27
CA2878640A1 (en) 2014-01-16
US9388231B2 (en) 2016-07-12
CN104768571A (zh) 2015-07-08
US20160207979A1 (en) 2016-07-21
AU2013289881A1 (en) 2015-02-26
CA2878640C (en) 2023-10-24
CN104768571B (zh) 2018-11-09
JP6498601B2 (ja) 2019-04-10
WO2014012082A2 (en) 2014-01-16
US20140066378A1 (en) 2014-03-06
US10358479B2 (en) 2019-07-23
WO2014012082A3 (en) 2014-04-03
AU2013289881B2 (en) 2018-01-18
US20190375823A1 (en) 2019-12-12
US11248037B2 (en) 2022-02-15

Similar Documents

Publication Publication Date Title
IN2015DN01115A (pm)
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
EA201190326A1 (ru) Полипептиды гормона роста и способы их получения и применения
WO2013184938A3 (en) Fusion polypeptides comprising mucin-domain polypeptide linkers
IN2014DN02043A (pm)
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
MY191428A (en) Antigen binding molecules comprising a tnf family ligand trimer
WO2013142859A3 (en) Fusion proteins of superfolder green fluorescent protein and use thereof
EA201491494A1 (ru) Нацеливание на гликаны хондроитинсульфаты
EA201691304A1 (ru) АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FcRn) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
IN2014DN09815A (pm)
MX2015006302A (es) Metodo para incrementar el volumen hidrodinamico de polipeptidos mediante la union a peptidos carboxi-terminales de gonadotrofina.
MX350962B (es) Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
NZ626945A (en) Chimeric factor viii polypeptides and uses thereof
IN2014CN00414A (pm)
BR112014019901A8 (pt) Proteínas de fator viii recombinante
AR092076A1 (es) Proteinas homodimericas
PE20121636A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
WO2014097113A3 (en) Production of therapeutic proteins in genetically modified mammalian cells
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
BR112015003724A2 (pt) polipeptídeo isolado, composição, uso de uma composição, polinucleotídeo isolado, constructo de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, e, métodos de produção de um polipeptídeo e de produção de uma proteína.